China's sinovac vaccine gets accolades, Johnson & Johnson jabbing linked for 23 blood clotting case

Anil Panchal FXStreet

As the global economy gradually overcomes the pandemic, except for India and Japan, Bloomberg came out with the report suggesting China’s coronavirus (COVID-19) vaccine from the Sinovac Biotech Ltd. as highly effective in the real-world study.

The report cites research on the Indonesian health workers and found over 96% got protected from hospitalization due to the jabbing. “Indonesia tracked 25,374 health workers in capital city Jakarta for 28 days after they received their second dose and found that the vaccine protected 100% of them from death and 96% from hospitalization as soon as seven days after, said Health Minister Budi Gunadi Sadikin in an interview on Tuesday. The workers were tracked until late February,” said Bloomberg.

Earlier Brazil was spotted cheering the Chinese vaccine while Chile criticized the pandemic’s cure.

Elsewhere, the US Centers for Disease Control and Prevention (CDC) found 23 blood clotting issues linked to the Johnson & Johnson inoculation while saying, “the benefits of the Johnson & Johnson vaccine outweigh the risks.”

It's worth mentioning that Brazil suspended the use of the AstraZeneca vaccine in pregnant women while Pfizer-BioNTech gets multiple orders from the Eurozone of late.

FX implications

Although the news should have ideally favored the market sentiment, the pre-US CPI caution seems to weigh on the mood.

Read: AUD/USD: Wavers above 0.7800 amid cautious sentiment on US Inflation day

Author

Anil Panchal

FXStreet

Anil Panchal has nearly 15 years of experience in tracking financial markets. With a keen interest in macroeconomics, Anil aptly tracks global news/updates and stays well-informed about the global financial moves and their implications.

AUD/USD recovers toward 0.7000 amid improving mood

AUD/USD is firming up toward 0.7000 in Asia on Tuesday, helped by improving market mood. A pause in the US Dollar rebound also aids the pair's upside. However, geopolitical risks and caution ahead of AI tech earnings report could limit the pair.

USD/JPY flatlines near 158.50 as markets seek direction

USD/JPY steadies around 158.50 in the Asian trading hours on Tuesday. Traders prefer to wait on the sidelines ahead of Japan’s National Consumer Price Index inflation data later on Friday. Meanwhile, elevated US bond yields provide some support to the US Dollar against the Japanese Yen.

Gold falls as bond yields regain ground ahead of Meta Q3 earnings

Gold price declines to near $4,120 in the European trade. The precious metal faces selling pressure amid a recovery in yields on United States bonds and rising oil prices. US Treasury Yields have shown signs of recovery, with US hyperscalers set to report their Q3 earnings in near time. As of writing, 10-year US Treasury Yields are down 0.35% to near 5.13%, but gained 1.2% on Monday.

NEAR Protocol: Mild correction persists despite resilient ETF inflows

NEAR Protocol price is down nearly 2% on Tuesday, mirroring its 2% decline from the previous day. Institutional demand remains firm, with Bitwise’s NEAR-focused Exchange Traded Fund (ETF) recording over $5 million in inflows on Monday.

Chip bounce fails to inspire Asia and France weighs on Europe

Preview: US chips rebound, but Europe and Asia slide; oil firms on Gulf supply fears. Risk caught a bid on Monday, buoyed by better-than-expected Chinese Q3 26 GDP growth and a rebound in chipmakers. US equity benchmarks recovered most of Friday’s lost ground, with the S&P 500 touching gloves with the underside of its 50-day SMA around 7,705 and the Nasdaq 100 leading the way, adding 1.2%.

The US Dollar fell. Gold didn't rally. That tells you everything

Gold (XAU/USD) is struggling to capitalize on a weaker US Dollar (USD), after repeatedly failing to establish itself above the $4,200 level. The precious metal remains confined to a relatively narrow trading range despite a combination of developments that would normally support higher prices.